Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats

Věra Čertíková Chábová, Agnieszka Walkowska, Elzbieta Kompanowska-Jezierska, Janusz Sadowski, Petr Kujal, Zdenka Vernerová, Zdeňa Vaňourková, Libor Kopkan, Herbert J. Kramer, John R. Falck, John D. Imig, Bruce D. Hammock, Ivana Vaněčková, Luděk Červenka

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12- dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.

Original languageEnglish (US)
Pages (from-to)617-632
Number of pages16
JournalClinical Science
Volume118
Issue number10
DOIs
StatePublished - May 2010

Fingerprint

Transgenic Rats
Hypertension
Acids
Angiotensin II
Kidney
Norepinephrine
Epoxide Hydrolases
20-hydroxy-5,8,11,14-eicosatetraenoic acid
Cardiomegaly
Sclerosis
Vasoconstrictor Agents
Vasodilator Agents
Proteinuria
Renin
Arachidonic Acid
Cytochrome P-450 Enzyme System
Hypertrophy
Biological Availability
Blood Vessels
Sprague Dawley Rats

Keywords

  • Cytochrome P450 (CYP450)
  • End-organ damage
  • Hypertension
  • Renin-angiotensin system (RAS)
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. / Čertíková Chábová, Věra; Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Kujal, Petr; Vernerová, Zdenka; Vaňourková, Zdeňa; Kopkan, Libor; Kramer, Herbert J.; Falck, John R.; Imig, John D.; Hammock, Bruce D.; Vaněčková, Ivana; Červenka, Luděk.

In: Clinical Science, Vol. 118, No. 10, 05.2010, p. 617-632.

Research output: Contribution to journalArticle

Čertíková Chábová, V, Walkowska, A, Kompanowska-Jezierska, E, Sadowski, J, Kujal, P, Vernerová, Z, Vaňourková, Z, Kopkan, L, Kramer, HJ, Falck, JR, Imig, JD, Hammock, BD, Vaněčková, I & Červenka, L 2010, 'Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats', Clinical Science, vol. 118, no. 10, pp. 617-632. https://doi.org/10.1042/CS20090459
Čertíková Chábová, Věra ; Walkowska, Agnieszka ; Kompanowska-Jezierska, Elzbieta ; Sadowski, Janusz ; Kujal, Petr ; Vernerová, Zdenka ; Vaňourková, Zdeňa ; Kopkan, Libor ; Kramer, Herbert J. ; Falck, John R. ; Imig, John D. ; Hammock, Bruce D. ; Vaněčková, Ivana ; Červenka, Luděk. / Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. In: Clinical Science. 2010 ; Vol. 118, No. 10. pp. 617-632.
@article{6d316d0e754a4c5ca204d430a070bcba,
title = "Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats",
abstract = "Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12- dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.",
keywords = "Cytochrome P450 (CYP450), End-organ damage, Hypertension, Renin-angiotensin system (RAS), Soluble epoxide hydrolase",
author = "{Čert{\'i}kov{\'a} Ch{\'a}bov{\'a}}, Věra and Agnieszka Walkowska and Elzbieta Kompanowska-Jezierska and Janusz Sadowski and Petr Kujal and Zdenka Vernerov{\'a} and Zdeňa Vaňourkov{\'a} and Libor Kopkan and Kramer, {Herbert J.} and Falck, {John R.} and Imig, {John D.} and Hammock, {Bruce D.} and Ivana Vaněčkov{\'a} and Luděk Červenka",
year = "2010",
month = "5",
doi = "10.1042/CS20090459",
language = "English (US)",
volume = "118",
pages = "617--632",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "10",

}

TY - JOUR

T1 - Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats

AU - Čertíková Chábová, Věra

AU - Walkowska, Agnieszka

AU - Kompanowska-Jezierska, Elzbieta

AU - Sadowski, Janusz

AU - Kujal, Petr

AU - Vernerová, Zdenka

AU - Vaňourková, Zdeňa

AU - Kopkan, Libor

AU - Kramer, Herbert J.

AU - Falck, John R.

AU - Imig, John D.

AU - Hammock, Bruce D.

AU - Vaněčková, Ivana

AU - Červenka, Luděk

PY - 2010/5

Y1 - 2010/5

N2 - Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12- dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.

AB - Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12- dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.

KW - Cytochrome P450 (CYP450)

KW - End-organ damage

KW - Hypertension

KW - Renin-angiotensin system (RAS)

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=77954063347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954063347&partnerID=8YFLogxK

U2 - 10.1042/CS20090459

DO - 10.1042/CS20090459

M3 - Article

C2 - 20050826

AN - SCOPUS:77954063347

VL - 118

SP - 617

EP - 632

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 10

ER -